Francesco Lo-Coco
Overview
Explore the profile of Francesco Lo-Coco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
12668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin W, Fordham S, Hungate E, Sunter N, Elstob C, Xu Y, et al.
Nat Commun
. 2022 Jan;
13(1):2.
PMID: 34983928
No abstract available.
2.
Lin W, Fordham S, Hungate E, Sunter N, Elstob C, Xu Y, et al.
Nat Commun
. 2021 Oct;
12(1):6233.
PMID: 34716350
Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating...
3.
Cicconi L, Testi A, Montesinos P, Rego E, Zhu H, Takahashi H, et al.
Blood Cancer J
. 2021 Oct;
11(10):167.
PMID: 34657125
No abstract available.
4.
Fabiani E, Cicconi L, Nardozza A, Cristiano A, Rossi M, Ottone T, et al.
Cancer Med
. 2021 May;
10(12):3839-3847.
PMID: 34042280
Background: The ZBTB16-RARA fusion gene, resulting from the reciprocal translocation between ZBTB16 on chromosome 11 and RARA genes on chromosome 17 [t(11;17)(q23;q21)], is rarely observed in acute myeloid leukemia (AML),...
5.
Weinhauser I, Pereira-Martins D, Ortiz C, Silveira D, Simoes L, Bianco T, et al.
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33120864
The SLIT-ROBO axis plays an important role in normal stem-cell biology, with possible repercussions on cancer stem cell emergence. Although the Promyelocytic Leukemia (PML) protein can regulate expression in the...
6.
Voso M, Larson R, Jones D, Marcucci G, Prior T, Krauter J, et al.
Blood Adv
. 2020 Oct;
4(19):4945-4954.
PMID: 33049054
The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid...
7.
Characterization of FLT3-ITD acute myeloid leukemia: molecular profiling of leukemic precursor cells
Travaglini S, Angelini D, Alfonso V, Guerrera G, Lavorgna S, Divona M, et al.
Blood Cancer J
. 2020 Aug;
10(8):85.
PMID: 32843624
Acute myeloid leukemia (AML) with FLT3-ITD mutations (FLT3-ITD) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors. In this disease, the CD34/CD123/CD25/CD99+...
8.
Gurnari C, Breccia M, Giuliano F, Scalzulli E, Divona M, Piciocchi A, et al.
Br J Haematol
. 2020 Aug;
193(1):129-132.
PMID: 32808672
Acute promyelocytic leukaemia (APL) represents a modern success of precision medicine. However, fatalities occurring within the first 30 days of induction treatment, in particular intracranial haemorrhage (ICH), remain the main...
9.
Thome C, Ferreira G, Pereira-Martins D, Augusto Dos Santos G, Ortiz C, de Souza L, et al.
Sci Rep
. 2020 Jun;
10(1):10315.
PMID: 32587277
Non-T cell activation linker (NTAL) is a lipid raft-membrane protein expressed by normal and leukemic cells and involved in cell signaling. In acute promyelocytic leukemia (APL), NTAL depletion from lipid...
10.
Falconi G, Fabiani E, Ottone T, Piciocchi A, Lavorgna S, Criscuolo M, et al.
Leuk Lymphoma
. 2019 Dec;
61(4):979-982.
PMID: 31797711
No abstract available.